toxicokinetics

Oncology

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

News

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.